Compare TVRD & DETX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TVRD | DETX |
|---|---|---|
| Founded | 2017 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Telecommunications Equipment |
| Sector | Health Care | Telecommunications |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.7M | 14.8M |
| IPO Year | 2013 | 2022 |
| Metric | TVRD | DETX |
|---|---|---|
| Price | $1.09 | $0.94 |
| Analyst Decision | Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $8.88 | N/A |
| AVG Volume (30 Days) | ★ 207.0K | 16.6K |
| Earning Date | 11-13-2026 | 11-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 79.01 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $911,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 959.30 | N/A |
| 52 Week Low | $0.77 | $1.15 |
| 52 Week High | $5.69 | $4.25 |
| Indicator | TVRD | DETX |
|---|---|---|
| Relative Strength Index (RSI) | 50.87 | 21.93 |
| Support Level | $0.85 | N/A |
| Resistance Level | $2.02 | $1.83 |
| Average True Range (ATR) | 0.17 | 0.18 |
| MACD | 0.05 | -0.01 |
| Stochastic Oscillator | 41.46 | 5.10 |
Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.
Liberty Defense Holdings Ltd is engaged in the development and commercialization of security detection technologies such as airports, stadiums, schools, and more. The company's Hexwave product utilizes millimeter wave technology and Advanced 3D imaging to detect concealed threats. In addition to HEXWAVE, the company has licensed High-Definition Advanced Imaging Technology (HD-AIT) for body and shoe scanning. The Company operates through three distinct segments: Corporate, HEXWAVE, and Contract. The company generates the majority of its revenue from the Contract segment. Geographically, the company generates the majority of its revenue from the United States.